Navigation Links
ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida
Date:10/29/2007

TOKYO, Oct. 29 /PRNewswire/ -- Aloka Co., Ltd., the Innovator in Ultrasound for more than 50 years, announced today the introduction of two ultrasound systems with dedicated platforms for advanced cardiac and vascular imaging, the ProSound Alpha 10 and the ProSound Alpha 7 at Scientific Session 2007 of American Heart Association, at the Orange County Convention Center in Orlando, Florida, November 4-7, 2007.

The ProSound Alpha 7 and the Alpha 10 incorporate all of the standard cardiovascular features such as stress echo, Tissue Doppler Imaging, Strain Imaging, Transesophageal echocardiography, full reporting capabilities and IHE & DICOM networking.

With important breakthrough flow display technology, the systems offer Directional eFLOW, D-eFLOW, a new innovative blood flow capture & display mode offering increased accuracy in blood flow detection of low velocity flow as well as acute acceleration. A standard new feature in these systems is the "Edge Optimizer" function, which improves dramatically the edge differentiation without compromise in temporal resolution. With high image definition and temporal resolution, the new ProSound systems offer a new level of diagnostic imaging in echocardiography.

The ProSound alpha 7 and alpha 10 offer a comprehensive cardio vascular analysis package.

More than ever, the cardiology community is recognizing the correlation between vascular diseases and the heart. The early detection of atherosclerosis could play a key role in preventing coronary artery disease, and peripheral arterial disease. Aloka has developed a technique that not only helps with early detection, but even helps to identify patients who are prone to atherosclerosis even before the usual clinical symptoms appear eTRACKING(TM) -- Echo Tracking is a proven technique that picks RF echo signals from blood vessels, tracks the motion of vessel walls, and measures changes in blood vessel diameter. Important parameters such as Pulse Wave Ve
'/>"/>

SOURCE Aloka Co., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

8

GOOD

Page: 1 2 3

Related biology technology :

1. GE Healthcare introduces MR imaging product
2. Online fishing site introduces interactive maps
3. GE introduces remotely hosted health services
4. Norlight introduces new e-mail security service
5. Angel network introduces ePlan
6. RedPrairie Corp. introduces new supply chain software
7. GE introduces compact ultrasound system for women
8. MailFoundry introduces new e-mail archive product
9. Madison biotech introduces drug discovery advance
10. Alfalight introduces new 25-watt pump module
11. Wisconsin introduces new state IT plan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Bio...the "Company") today announced updated results fro...atients with sarcomas metastatic to the lung in a ...Tissue Oncology Society Meeting held in Miami Beac...resentation, entitled "A Phase II Study of Intrave...
(Date:11/5/2009)...ERSBURG, Md., Nov. 5 Gen...ancial results for the third quarter ended Septemb...llion ($0.04 per share) for the three months ended... million ($0.08 per share) in the comparable quart..., 2009, GenVec,s net loss was $14.1 million ($0.15...
(Date:11/5/2009)...O CORDOVA, Calif., Nov. 5 /PRNewswire-FirstCall/ -...supplier of innovative products for processing and...for the first quarter of fiscal 2010. ,, For th...ported revenues of $5.2 million, a 15 percent incr...arter a year ago. The Company said the key contrib...
(Date:11/5/2009)...VALE, Calif., Nov. 5 Cep...cutives will be speaking at the following investor... via webcast. , , Credit Suisse He...Thursday, 12 November, 2009 at 10 a.m. Mountain Ti...ram, London, England, Tuesday, 1 D...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2
...EAST NORRITON, Pa., Feb. 27 Tengion Inc., a clini... the development of,neo-organs and neo-vessels, an...o its Board of Directors. Mr. Randall brings more ...ive, CFO and CEO at public and private,companies t...device,manufacturing and electronics industries., ...
...SOUTH SAN FRANCISCO, Calif., Feb. 27 Anesiva,Inc....aughlin, the company,s,chief executive officer, wi...ificant Investment Options in Healthcare Conferenc...., To access the live webcast or the subsequent a...om, go to the Investors page, and click on Events...
...RIO DE JANEIRO, Brazil, Feb. 26 One of,Brazil,s l...ofarma,Distribuidora de Produtos Farmaceuticos S.A...as just announced its results for the fourth quart...S FOR THE PERIOD, -- Profarma,s market share brea...ntage points above the share reached in the 3Q07 a...
Other Biology Technology:Tengion Appoints Jeff Randall to Board of Directors 2
(Date:11/4/2009)...,, CARLSBAD, Calif., Oct. 23 Ge...ure biosample management for genomic discovery, me...vid Wellis, Ph.D., GenVault,s President and CEO, w...e taking place on October 26th and 27th in La Joll...ill provide an overview of the company together wi...
(Date:11/4/2009)...,, NEW YORK, Oct. 27 Global Rai...mpany and advanced R&D laboratory, today annou...e and is prepared to actively commercialize its su...dge biometric security offerings. ,, During the...llions of dollars to develop and deploy a series o...
(Date:11/4/2009)...,, CARLSBAD, Calif., Nov. 4 Gen...hat William Brody, M.D., Ph.D., has joined its Boa...idential Chair of the Salk Institute, is an acclai...ior to joining the Salk Institute, Dr. Brody serve...e is a member of the National Academy of Engineeri...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Brain Fitness Makes Boomers Age Younger 4605 1Brain Fitness Makes Boomers Age Younger 4605 2BioArts International Clones 9 11 Hero Dog Owner to Receive Five Cloned Puppies June 17 in Los Angeles 49158 1BioArts International Clones 9 11 Hero Dog Owner to Receive Five Cloned Puppies June 17 in Los Angeles 49158 2BioArts International Clones 9 11 Hero Dog Owner to Receive Five Cloned Puppies June 17 in Los Angeles 49158 3European Airports Actively Engaging on Reducing CO2 Despite the Crisis 12664 1European Airports Actively Engaging on Reducing CO2 Despite the Crisis 12664 2European Airports Actively Engaging on Reducing CO2 Despite the Crisis 12664 3
...n damage DNA, reducing its ability to replicate an...he development of skin cancers. However, not much ...s altered upon exposure to UV light. Now a group o...method to measure changes in the mechanical proper...r Marszalek and his colleagues have conducted sing...
...MS) tends to go into remission while women are pre...ing neurodegenerative disease, according to Univer...pregnancy-related hormone is responsible for rebui... In a paper to be published in the February 21 iss...rchers from the U of C,s Faculty of Medicine repor...
...ther, more widely used subjects of scientific stud... or mouse. But University of Illinois cell and dev...s it should be. As it turns out, the tiny, seeming... study of germ cells, precursors of eggs and sperm...arian Newmark studies, Schmidtea mediterranea, is ...
Other Biology News:Stretching DNA to the limit 2Pregnancy hormone key to repairing nerve cell damage 2Pregnancy hormone key to repairing nerve cell damage 3Study of planarians offers insight into germ cell development 2
Mycoplasma Testing from AbD Serotec
...Exonuclease-free Klenow Fragment is a genetically ...xonuclease activity has been removed, leaving only...f exonuclease activity makes Exo- Klenow Fragment ...ng of DNA probes by the random primed method, and ...
T4 RNA Ligase from Roche Applied Science
T7 RNA Polymerase from Roche Applied Science
Biology Products: